Intercept Pharmaceuticals (ICPT) Bullish View Reiterated at Needham & Company on Positive Positive Phase 3 REGENERATE NASH Trial

Intercept Pharma (ICPT) Gives Back Most of NASH Trial Gains

Intercept Pharma (NASDAQ: ICPT) is seeing heavy pressure today following upside Tuesday after the company announced positive NASH trial results. Shares were last down 9% to $107.05 after closing at $110.82 on Friday, before the data was released Tuesday morning.

Intercept Pharmaceuticals (ICPT) PT Raised to $149 at Cowen

Cowen analyst Ritu Baral raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $149.00 (from $120.00) while maintaining a Outperform rating.

The analyst commented, "ICPT's Ph3 NASH trial REGENERATE reported positive data this morning, achieving statistically significant fibrosis (with no... More

Intercept Pharmaceuticals (ICPT) PT Raised to $248 at Wedbush

Wedbush analyst Liana Moussatos raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $248.00 (from $220.00) while maintaining a Outperform rating.

Intercept Pharmaceuticals (ICPT) PT Raised to $175 at Oppenheimer; 'REGENERATE Top Line Sparks Joy'

Oppenheimer analyst Jay Olson raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $175.00 (from $140.00) while maintaining a Outperform rating.

The analyst commented, "Top line results from the Ph3 REGENERATE study of OCA in NASH were stat sig for Fibrosis... More

Intercept Pharma (ICPT) Estimates Raised At Baird

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) after patients receiving 25mg of OCA showed an impressive benefit on fibrosis, the more important of the two prospectively defined efficacy endpoints. One of the two primary endpoints, a 1 stage... More

Viking Therapeutics (VKTX) Trades Higher Following Positive Results From Intercept Pharma (ICPT)

Viking Therapeutics (NASDAQ: VKTX) traded higher following positive results from Intercept Pharma (NASDAQ: ICPT). Intercept gained 20% and Viking climbed 4.2%.

Intercept Pharma (ICPT) Announces Phase 3 REGENERATE Study in NASH Met Primary Endpoint

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced positive results from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). In the primary efficacy analysis, once-daily OCA 25 mg met the primary endpoint of fibrosis improvement (1 stage) with no worsening of NASH at the planned 18-month interim analysis (p=0.0002 vs. placebo). In the primary efficacy analysis, a numerically greater proportion of patients in both OCA treatment arms compared to placebo achieved the primary endpoint of NASH resolution with no worsening of liver fibrosis, but this did not reach... More